课题基金 / 基金详情

ALTERATIONS IN DOPAMINERGIC RESPONSE IN PARKINSONISM

ALTERATIONS IN DOPAMINERGIC RESPONSE IN PARKINSONISM
帕金森症多巴胺能反应的改变
批准号:
2259442
负责人:
STEPHEN T GANCHER
金额:
$9.4万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-01-01 至 1996-12-31

项目摘要

项目成果

STEPHEN T GANCHER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The chronic treatment of Parkinson's disease with levodopa commonly is associated with the development of motor fluctuations and dyskinesias. The reason for these motor effects is unclear, but it is possible that these responses represent the development of tolerance and sensitization to dopaminergic stimulation resulting from chronic drug exposure. This proposal will examine the relationship between alterations in dopaminergic response and the degree of dopaminergic lesioning, the dose and frequency of dopaminergic stimulation, and changes in the content of substance P, a peptide found in the basal ganglia that is thought to modulate dopaminergic neurotransmission. Dr. Gancher has investigated the pharmacology of apomorphine and levodopa in patients with Parkinson's disease and has evidence to suggest the existence of dopaminergic tolerance. The long-term objectives are to obtain training in basic science techniques to allow studies of behavioral, morphological, and biochemical changes in the basal ganglia resulting from chronic treatment, to develop better treatments for motor fluctuations and dyskinesias. This proposal will allow Dr. Gancher to acquire basic science skills and experience to develop his own independent research program that will complement but not duplicate existing research programs at the university. Training in biochemical and animal surgical techniques will be obtained under the supervision of Dr. William Woodward, a neuroscientist with expertise in HPLC using electrochemical detection and brain morphometry. Dr Gajanan Nilaver will provide training in immunohistochemistry, brain mapping, and animal lesioning. Dr. John Crabbe, an authority on ethanol tolerance, will provide guidance in experimental design and interpretation. Dr. John Nutt, a clinical neuropharmacologist and expert in Parkinson's disease will serve as Dr. Gancher's sponsor. Oregon Health Sciences University and affiliated institutions (the Vollum Institute and the Portland VA) has a major interest in the neurosciences and is a robust research environment for additional collaborative studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
ALTERATIONS IN DOPAMINERGIC RESPONSE IN PARKINSONISM
海外基金